Keith G Tolman
Affiliation: University of Utah
- Treatment of non-alcoholic fatty liver diseaseKeith G Tolman
Division of Gastroenterology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA
Ther Clin Risk Manag 3:1153-63. 2007..There are fewer, but promising data, with statins which have been shown to be hepatoprotective in other liver diseases. The initial enthusiasm for ursodeoxycholic acid has not been supported by histologic studies...
- Hepatotoxicity of the thiazolidinedionesKeith G Tolman
Division of Gastroenterology, Department of Internal Medicine, University of Utah School of Medicine, 30 N 1900 E RM 4R118 SOM Salt Lake City, UT 84132, USA
Clin Liver Dis 7:369-79, vi. 2003..All of the thiazolidinediones cause ALT elevations; however, ALT monitoring for hepatotoxicity does not appear to prevent serious liver disease nor reduce patient risk...
- Narrative review: hepatobiliary disease in type 2 diabetes mellitusKeith G Tolman
University of Utah and University Hospitals and Clinics, Salt Lake City, Utah 84132, USA
Ann Intern Med 141:946-56. 2004....
- Comparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteersKeith G Tolman
University of Utah School of Medicine, Salt Lake City, Utah, USA
Clin Drug Investig 26:21-8. 2006....
- Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver diseaseKeith G Tolman
Division of Gastroenterology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA
Diabetes Care 30:734-43. 2007
- Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the USKeith G Tolman
University of Utah, Salt Lake City, Utah, USA
Drug Saf 32:787-800. 2009..We conducted a randomized, long-term, double-blind, hepatic safety study at 171 centres in the US in which 2097 patients with type 2 diabetes received either pioglitazone or glibenclamide (glyburide)...
- The liver and lovastatinKeith G Tolman
University of Utah School of Medicine, Salt Lake City, Utah 84132, USA
Am J Cardiol 89:1374-80. 2002..In fact, it may increase patient risk because of needless discontinuation of cholesterol-lowering therapy for false-positive results in patients who are benefiting from treatment...
- Reply to Dr. Dujovne's editorialKeith G Tolman
Am J Cardiol 89:1452. 2002
- The therapeutic use of acetaminophen in patients with liver diseaseGordon D Benson
Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, 401 Haddon Avenue, Camden, NJ 08103, USA
Am J Ther 12:133-41. 2005....